Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075350 | 0.96 | PLA2G2A (0.44) | DHODHPDE10APLA2G2A | |
| SCHEMBL26075343 | 0.92 | PLA2G2A (0.39) | DHODHPDE10APLA2G2A | |
| SCHEMBL26075330 | 0.91 | PLA2G2A (0.41) | DHODHPDE10APLA2G2A | |
| SCHEMBL26075234 | 0.89 | DHODH (0.44) | DHODHPDE10APLA2G2A | |
| SCHEMBL26075357 | 0.85 | PLA2G2A (0.42) | DHODHPDE10APLA2G2A | |
| SCHEMBL23590088 | 0.85 | DHODH (0.64) | DHODHPDE10APLA2G2A | |
| SCHEMBL26075362 | 0.85 | PLA2G2A (0.41) | DHODHPDE10APLA2G2A | |
| SCHEMBL26075360 | 0.85 | PLA2G2A (0.41) | DHODHPDE10APLA2G2A | |
| SCHEMBL26075354 | 0.85 | PLA2G2A (0.41) | DHODHPDE10APLA2G2A | |
| SCHEMBL26075365 | 0.85 | PLA2G2A (0.41) | DHODHPDE10APLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | DHODH 1/4885PDE10A 3462/4885PLA2G2A 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.